dacarbazine,pegfilgrastim,doxorubicin,nivolumab,brentuximab vedotin,vinblastine,filgrastim
amgen,bms,seagen
['cml']
herrera. n-avd vs bv-avd. 1/4 of pts &lt;18yrs. pfs 94% vs 86%. efs 91% vs 84%. at 1 yr. os no diff yet. less tox fr n-avd.
historical data. seems an easy choice, at least if bv-avd is your std. nb short follow up.
#17icml 
Oncologist at Uppsala university hospital. Chair of the Swedish lymphoma group (SLG) and the Swedish Hodgkin lymphoma group.